Lead Product(s) : Trichostatin A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vanda Pharmaceuticals Receives FDA Approval for VTR-297 in Onychomycosis
Details : VTR-297 (trichostatin A) is a small molecule histone deacetylase (HDAC) inhibitor with activity against dermatophytes and fungi. It is being evaluated in phase 2 clinical trials for Onychomycosis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2024
Lead Product(s) : Trichostatin A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trichostatin A
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 12, 2019
Lead Product(s) : Trichostatin A
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable